About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: STML
- Previous Close: $7.00
- 50 Day Moving Average: $8.84
- 200 Day Moving Average: $10.49
- 52-Week Range: $4.06 - $14.60
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.41
- P/E Growth: 0.00
- Market Cap: $124.92M
- Outstanding Shares: 17,846,000
- Beta: 0.13
- Net Margins: -4,058.44%
- Return on Equity: -50.06%
- Return on Assets: -44.60%
Companies Related to Stemline Therapeutics:
- Current Ratio: 5.60%
- Quick Ratio: 5.60%
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?
7 equities research analysts have issued 12 month target prices for Stemline Therapeutics' shares. Their predictions range from $11.00 to $34.00. On average, they anticipate Stemline Therapeutics' stock price to reach $23.25 in the next year.
When will Stemline Therapeutics announce their earnings?
Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (2/9/2017)
Jefferies Group LLC analysts commented, "We had a chance to host investor meetings with mgmt, which primarily focused on near-term SL-401 catalysts. In BPDCN, the focus was around the pot’l 2H16 meeting with FDA to determine the amount of data needed to submit a BLA. The company also presented incrementally updated data in BPDCN that was consistent with data from ASCO." (7/22/2016)
Who owns Stemline Therapeutics stock?
Stemline Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.27%), Franklin Resources Inc. (8.12%), Eventide Asset Management LLC (4.77%), State Street Corp (1.41%), J. Goldman & Co LP (1.12%) and Bogle Investment Management L P DE (0.53%). Company insiders that own Stemline Therapeutics stock include David Gionco, Eric K Rowinsky, Ivan Bergstein and Kenneth Hoberman.
Who sold Stemline Therapeutics stock? Who is selling Stemline Therapeutics stock?
Stemline Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Dimensional Fund Advisors LP and Paradigm Asset Management Co. LLC. Company insiders that have sold Stemline Therapeutics stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman.
Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?
Stemline Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Bogle Investment Management L P DE, Oxford Asset Management, State Street Corp, Ladenburg Thalmann Financial Services Inc., Perceptive Advisors LLC and Renaissance Technologies LLC.
How do I buy Stemline Therapeutics stock?
Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Stemline Therapeutics stock cost?
One share of Stemline Therapeutics stock can currently be purchased for approximately $7.00.